title: Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
abstract: Twenty-eight patients (12 men with prostate cancer, 16 women with breast cancer) were included in a phase II trial to evaluate the efficacy of 186Re-hydroxyethylidene diphosphonate (HEDP) on pain from bone metastasis and the toxicity of this agent.
  
  
  METHODS
  After intravenous administration of 1295 MBq 186Re-HEDP, the efficacy was evaluated by means of a daily log.
  
  
  RESULTS
  We observed an objective response in 67% of prostate cancer patients and in 36% of breast cancer patients. The mean duration of response was 45 d for prostate cancer patients and 24 d for breast cancer patients. No major adverse effects were observed. Marrow toxicity did not exceed grade 2 for white blood cells and grade 3 for platelets using National Cancer Institute criteria.
  
  
  CONCLUSIONS
  186Re-HEDP provides safe symptomatic relief of pain in prostate cancer patients. The benefit of this treatment is less clear in breast cancer patients. Further studies should be conducted to evaluate treatment by 186Re-HEDP at an earlier stage of the disease.
authors.affiliation: Department of Nuclear Medicine, Henri Mondor Hospital, Crêteil, France.
authors.forename: H
authors.initials: H
authors.lastname: Kolesnikov-Gauthier
authors.forename: P
authors.initials: P
authors.lastname: Carpentier
authors.forename: P
authors.initials: P
authors.lastname: Depreux
authors.forename: P
authors.initials: P
authors.lastname: Vennin
authors.forename: A
authors.initials: A
authors.lastname: Caty
authors.forename: C
authors.initials: C
authors.lastname: Sulman
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology; D000368:Aged; D001859:Bone Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000473:pathology*; D012968:Etidronic Acid / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009942:Organometallic Compounds; D010166:Palliative Care / Q000379:methods*; D011471:Prostatic Neoplasms / Q000473:pathology*; D011868:Radioisotopes / Q000627:therapeutic use* / Q000633:toxicity; D019275:Radiopharmaceuticals / Q000627:therapeutic use* / Q000633:toxicity; D012211:Rhenium / Q000627:therapeutic use* / Q000633:toxicity; D013997:Time Factors
chemical_list: D009942:Organometallic Compounds; D011868:Radioisotopes; D019275:Radiopharmaceuticals; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid